Skip to content
Quebec News Tribune – Lifestyle
Author:
Rapport Therapeutics, Inc.
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
October 20, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 8, 2026
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
April 1, 2026